Navigation Links
Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Date:1/4/2012

BLUE BELL, Pa., Jan. 4, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that it has promoted Niranjan Y. Sardesai, Ph.D., from Senior Vice President Research and Development to Chief Operating Officer. In his expanded role, Dr. Sardesai will be responsible for corporate and business development for the company in addition to continuing to oversee research and development. Inovio also announced the retirement of Kevin W. Rassas, former Senior Vice President Business Development.

Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, said, "Niranjan brings to the COO position a strong combination of strategic business, transactional, and technical skills and broad operating experience. He has overseen the integration, development, and growth of Inovio's pipeline through the advancement of its proprietary technology as well as licensing and M&A efforts. We are pleased to have him assume this broader responsibility to help guide and execute Inovio's business plan to develop important new vaccines. Kevin played a vital role in the formative years of our predecessor company, VGX Pharmaceuticals, bringing big Pharma management experience to an entrepreneurial environment, and subsequently in advancing Inovio's key business relationships. We thank him for his contribution and commitment to Inovio and wish him the very best in the future."

Dr. Sardesai has broad operating and consulting experience in biotechnology and pharmaceuticals. He joined VGX Pharmaceuticals as VP Research and Development in 2006, was promoted to SVP R&D in 2007 and, with the merger of VGX with Inovio in June 2009, became SVP Research & Development of the merged company. Dr. Sardesai is responsible for leading the company's product development programs in infectious disease and cancer vaccines and vaccine delivery systems. He has secured ov
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
2. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
3. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
4. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
5. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
6. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... NYSE: SNY) today announced that the Companies intend to ... pediatric disease priority review voucher in connection with the ... review voucher entitles the holder to designate a BLA ... review from the filing date instead of the standard ...
(Date:7/30/2014)... 30, 2014  Replikins Ltd. today released new data ... virus. Before the current outbreaks, the mean Ebola Reston ... acids) between 1995 and 2002 was 1.1; the mean ... and sixteen-fold in 2013, thus predicting the current outbreaks ... has been shown to be able to predict outbreaks ...
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
Breaking Biology Technology:Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... 2012  Foundation for Health Improvement and Technology (FHIT), ... its nonprofit, with the mission to rid the ... through educational programs promoting early detection and aggressive ... research have made it entirely possible to detect ...
... Francisco, CA (March 14, 2012): A highly targeted ... O104 strain was rapidly created using AvidBiotics, antibacterial ... published, draft genomic sequence data as detailed in a ... strategy described offers a rapid-response platform with the potential ...
... of a specialist field to identify subject experts and ... bewildering. New research, published in BioMed Central,s open access ... method of social network analysis, similar to finding friends ... news articles to identify opinion leaders and media experts. ...
Cached Biology Technology:Foundation for Health Improvement and Technology (FHIT) Launched to Beat Cardiovascular Disease 2Targeted antibacterial agent rapidly created in response to serious food safety pathogen 2Targeted antibacterial agent rapidly created in response to serious food safety pathogen 3Social networking shortcut to finding medical experts 2
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
(Date:7/30/2014)... State University,s College of Engineering recently received a ... the project, "Nanoparticle-directed synthesis of organic nanorods." ... is the creation and utilization of functional materials, ... A major bottleneck in scaling up nanotechnology is ... functional materials into one device. A research team ...
(Date:7/30/2014)... Embryonic stem cells can develop into a multitude of cells ... development into the specific types of mature cells that make ... , One key seems to be long chains of sugars ... Godula,s group at the University of California, San Diego, has ... sugars, but can be more easily manipulated to direct the ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... New South Wales (UNSW) researchers have announced they are developing ... to treat a diverse range of health problems, from inflammation ... is published in the July issue of Nature Biotechnology. ... age-related macular degeneration (AMD) and diabetic retinopathy are likely to ...
... Physicians and surgeons will someday monitor a patient's blood ... thanks to research being conducted by a Cornell University ... new technology is being developed by Edwin Kan, associate ... Transonic Systems of Ithaca. Kan performed much of his ...
... factors that would explain the different life expectancies of ... universal, according to University of Michigan researchers. , "Women ... difference in lifespan has been recognized since at least ... scientist in the U-M School of Public Health and ...
Cached Biology News:'Molecular assassin' targets disease gene 2Researchers to develop ultra-miniature implantable sensors to measure blood flow 2Evolutionary forces explain why women live longer than men 2